Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost-effectiveness

被引:24
作者
Gerli, S [1 ]
Casini, ML
Unfer, V
Costabile, L
Mignosa, M
Di Renzo, GC
机构
[1] Univ Perugia, Ctr Reprod & Perinatal Med, Dept Gynecol Obstet & Pediat Sci, I-06100 Perugia, Italy
[2] Univ Roma La Sapienza, Dept Human Physiol & Pharmacol Vittorio Erspamer, Rome, Italy
[3] AGUNCO, Obstet & Gynaecol Ctr, Rome, Italy
关键词
cost-effectiveness; intrauterine insemination; ovarian stimulation; PCOS; recombinant FSH; urinary FSH;
D O I
10.1016/S1472-6483(10)61632-X
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The aim of this prospective, randomized trial was to compare the clinical results and the cost-effectiveness of urinary FSH (uFSH) and recombinant FSH (rFSH) in ovarian stimulation for intrauterine insemination (IUI) cycles in polycystic ovary syndrome (PCOS) patients. One-hundred and seventy PCOS infertile patients undergoing IUI were enrolled, and protocols of ovarian stimulation with uFSH or rFSH were randomly assigned. The total number of cycles performed was 379 (182 and 197, respectively). The main outcome measures were the number of mature follicles, the days of stimulation, the number of ampoules and IU used per cycle, the biochemical/clinical pregnancy rates, the number of multiple pregnancies and the cost-effectiveness. No statistically significant differences were found in the follicular development, length of stimulation, pregnancy rates, delivery rates and multiple pregnancies between the two groups. In the uFSH group, the cost per cycle remained significantly lower (218.51 +/- 88.69 Euro versus 312.22 +/- 118.12 Euro; P < 0.0001), even though a significantly higher number of IU of gonadotrophins were used (809.3 +/- 271.9 versus 589.1 +/- 244.7; P < 0.0001). The cost-effectiveness (i.e. within a group, the total cost of all cycles divided by no. of clinical pregnancies) was 1729.08 in the uFSH group and 3075.37 in the rFSH group. In conclusion, uFSH and rFSH demonstrated the same effectiveness in ovarian stimulation in IUI cycles in PCOS patients. The urinary preparation is more cost-effective due to the difference of its cost per IU.
引用
收藏
页码:494 / 499
页数:6
相关论文
共 50 条
[21]   Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials [J].
Palomba, Stefano ;
Falbo, Angela ;
La Sala, Giovanni B. .
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2014, 12
[22]   Long-term follow-up of laparoscopic electrocautery of the ovaries versus ovulation induction with recombinant FSH in clomiphene citrate-resistant women with polycystic ovary syndrome: an economic evaluation [J].
Nahuis, M. J. ;
Lohuis, E. Oude ;
Kose, N. ;
Bayram, N. ;
Hompes, P. ;
Oosterhuis, G. J. E. ;
Kaaijk, E. M. ;
Cohlen, B. J. ;
Bossuyt, P. P. M. ;
van der Veen, F. ;
Mol, B. W. ;
van Wely, M. .
HUMAN REPRODUCTION, 2012, 27 (12) :3577-3582
[23]   Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial [J].
Balen, Adam ;
Platteau, Peter ;
Andersen, Anders Nyboe ;
Devroey, Paul ;
Helmgaard, Lisbeth ;
Arce, Joan-Carles .
HUMAN REPRODUCTION, 2007, 22 (07) :1816-1823
[24]   Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial [J].
Pacchiarotti, Alessandro ;
Sbracia, Marco ;
Frega, Antonio ;
Selman, Helmy ;
Rinaldi, Leonardo ;
Pacchiarotti, Arianna .
FERTILITY AND STERILITY, 2010, 94 (06) :2467-2469
[25]   NEWS AROUND THE WORLD: Reflections on the Cost-Effectiveness of Recombinant FSH in Assisted Reproduction. The Clinician's Perspective [J].
Juan Balasch ;
Pedro N. Barri .
Journal of Assisted Reproduction and Genetics, 2001, 18 :45-55
[26]   Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: A pilot prospective study [J].
Anna Maria Fulghesu ;
M. Ciampelli ;
C. Belosi ;
R. Apa ;
M. Guido ;
A. Caruso ;
S. Mancuso ;
A. Lanzoneal .
Journal of Endocrinological Investigation, 2001, 24 :483-490
[27]   Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: A pilot prospective study [J].
Fulghesu, AM ;
Ciampelli, M ;
Belosi, C ;
Apa, R ;
Guido, M ;
Caruso, A ;
Mancuso, S ;
Lanzone, A .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2001, 24 (07) :483-490
[28]   Cost-effectiveness analysis of polycystic ovary syndrome management and the risk of gestational diabetes in pregnant women: a decision-tree model [J].
Alenzi, Ebtihag O. .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) :995-999
[29]   The impact of a gonadotropin-releasing hormone antagonist on gonadotropin ovulation induction cycles in women with polycystic ovary syndrome: a prospective randomized study [J].
Stadtmauer, Laurel A. ;
Sarhan, Abbaa ;
Duran, E. Hakan ;
Beydoun, Hind ;
Bocca, Silvina ;
Pultz, Beth ;
Oehninger, Sergio .
FERTILITY AND STERILITY, 2011, 95 (01) :216-220
[30]   Early prediction of ovarian multifollicular response during ovulation induction in patients with polycystic ovary syndrome [J].
Farhi, J ;
Jacobs, HS .
FERTILITY AND STERILITY, 1997, 67 (03) :459-462